Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.60 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8781086 | 0.86 | MTNR1A (0.52) | ACKR3APPMTNR1AMTNR1B | |
| SCHEMBL13135957 | 0.84 | SIGMAR1 (0.63) | TMEM97SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL18052439 | 0.82 | L3MBTL1 (0.48) | TMEM97SIGMAR1MAPT | |
| SCHEMBL13115918 | 0.80 | SIGMAR1 (0.59) | TMEM97SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL17117270 | 0.79 | MEN1 (0.64) | TMEM97SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL17086584 | 0.79 | SIGMAR1 (0.58) | TMEM97SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL15348637 | 0.79 | SIGMAR1 (0.58) | TMEM97SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL24029812 | 0.78 | TMEM97 (0.56) | TMEM97SIGMAR1ACKR3MEN1KMT2A | |
| SCHEMBL13302989 | 0.78 | SIGMAR1 (0.56) | TMEM97SIGMAR1MEN1KMT2ARAB9A | |
| SCHEMBL9777548 | 0.78 | TMEM97 (0.60) | TMEM97SIGMAR1ACKR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-04 | — | — | US | claimed |
| US-6638965-B2 | Antitumor agents | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-10-28 | — | — | US | claimed |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044053-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | TMEM97 2317/4885SIGMAR1 1330/4885ACKR3 4208/4885 |
| US-20040044222-A1 | New substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, MKI67, CSNK1A1 | TMEM97 2317/4885SIGMAR1 1330/4885ACKR3 4208/4885 |
| US-20030069299-A1 | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | CCNI, CSNK1A1, MKI67 | TMEM97 3193/4885SIGMAR1 1815/4885ACKR3 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.